Work

Targeting Neuropilin-1 with EG00229 Attenuates Pulmonary Arterial Hypertension in a Murine Sugen/Hypoxia Model

Year: 2026
Type: article
Abstract: Pulmonary arterial hypertension (PAH) is a progressive vasculopathy driven by pulmonary vascular remodeling that leads to right ventricular failure and premature death. Despite improvements with therapies targeting the three canonical vasoactive pathways (nitric oxide, endothelin, and prostacyclin)─including endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, soluble guanylyl cyclase stimulators, and prostacyclin analogues─most patients do not achieve disease remission. This highlights the critical need for disease-modifying approaches that directly target and reverse pathological vascular remodeling. Recent advances, including the approval of the activin-signaling inhibitor sotatercept, suggest the feasibility of strategies that target novel antiremodeling pathways; however, PAH remains incurable for the vast majority. Neuropilin-1 (NRP1) is a multifunctional coreceptor expressed by endothelial cells (ECs) and pulmonary artery smooth muscle cells (PASMCs). The receptor orchestrates intracellular signaling by binding multiple ligands implicated in PAH pathobiology, including vascular endothelial growth factor (VEGF)-A, transforming growth factor (TGF)-β family members and platelet-derived growth factors (PDGFs), and modulates endothelial junctional stability, permeability and smooth muscle cell migration Here, we show that NRP1 is overexpressed in pulmonary artery smooth muscle cells from patients with PAH and that pharmacological inhibition of NRP1 with the novel small-molecule antagonist EG00229 attenuates hemodynamic and structural features of the disease in the gold-standard Sugen 5416/hypoxia (SuHx) mouse model of PAH. EG00229 reduced right-ventricular systolic pressure, right ventricular hypertrophy, and pulmonary arterial muscularization without affecting systemic blood pressure or body weight, supporting on-target pulmonary selectivity. These findings identify NRP1 as a tractable therapeutic target with potential to modulate vascular remodeling in PAH.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W7236802795
FWCI:
Cites: 34
Cited by:
Related to: 10